Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

被引：0

作者：

Jesper van Breeschoten

Michel W. J. M. Wouters

Doranne L. Hilarius

John B. Haanen

Christian U. Blank

Maureen J. B. Aarts

Franchette W. P. J. van den Berkmortel

Jan-Willem B. de Groot

Geke A. P. Hospers

Ellen Kapiteijn

Djura Piersma

Roos S. van Rijn

Karijn P. M. Suijkerbuijk

Willeke A. M. Blokx

Bert-Jan J. ten Tije

Astrid A. M. van der Veldt

Art Vreugdenhil

Marye J. Boers-Sonderen

Alfonsus J. M. van den Eertwegh

机构：

[1] Dutch Institute for Clinical Auditing,Department of Medical Oncology

[2] Amsterdam UMC,Department of Surgical Oncology

[3] VU University Medical Center,Department of Pharmacy

[4] Cancer Center Amsterdam,Department of Medical Oncology and Immunology

[5] Netherlands Cancer Institute,Department of Molecular Oncology & Immunology

[6] Rode Kruis Ziekenhuis,Department of Medical Oncology

[7] Netherlands Cancer Institute,Department of Medical Oncology

[8] Netherlands Cancer Institute,Department of Medical Oncology

[9] Maastricht University Medical Centre,Department of Medical Oncology

[10] Zuyderland Medical Centre Sittard,Department of Internal Medicine

[11] Isala Oncology Center,Department of Internal Medicine

[12] Isala,Department of Medical Oncology

[13] University Medical Centre Groningen,Department of Pathology, Division of Laboratories

[14] Leiden University Medical Centre,Department of Internal Medicine

[15] Medisch Spectrum Twente,Departments of Medical Oncology and Radiology & Nuclear Medicine

[16] Medical Centre Leeuwarden,Department of Internal Medicine

[17] University Medical Centre Utrecht,Department of Medical Oncology

[18] Pharmacy and Biomedical Genetics,undefined

[19] University Medical Center Utrecht. Heidelberglaan 100,undefined

[20] Amphia Hospital,undefined

[21] Erasmus Medical Centre,undefined

[22] Maxima Medical Centre,undefined

[23] Radboud University Medical Centre,undefined

来源：

British Journal of Cancer | 2022年 / 126卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1362 / 1362

共 42 条

[1] Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten
Michel W. J. M. Wouters
Doranne L. Hilarius
John B. Haanen
Christian U. Blank
Maureen J. B. Aarts
Franchette W. P. J. van den Berkmortel
Jan-Willem B. de Groot
Geke A. P. Hospers
Ellen Kapiteijn
Djura Piersma
Roos S. van Rijn
Karijn P. M. Suijkerbuijk
Willeke A. M. Blokx
Bert-Jan J. ten Tije
Astrid A. M. van der Veldt
Art Vreugdenhil
Marye J. Boers-Sonderen
Alfonsus J. M. van den Eertwegh
British Journal of Cancer, 2021, 124 : 1746 - 1746
[2] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
Tije, Bert-Jan J. ten
Veldt, Astrid A. M. van der
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
BRITISH JOURNAL OF CANCER, 2021, 124 (07) : 1222 - 1230
[3] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten
Michel W. J. M. Wouters
Doranne L. Hilarius
John B. Haanen
Christian U. Blank
Maureen J. B. Aarts
Franchette W. P. J. van den Berkmortel
Jan-Willem B. de Groot
Geke A. P. Hospers
Ellen Kapiteijn
Djura Piersma
Roos S. van Rijn
Karijn P. M. Suijkerbuijk
Willeke A. M. Blokx
Bert-Jan J. ten Tije
Astrid A. M. van der Veldt
Art Vreugdenhil
Marye J. Boers-Sonderen
Alfonsus J. M. van den Eertwegh
British Journal of Cancer, 2021, 124 : 1222 - 1230
[4] First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
Breeschoten, J. V.
Wouters, M.
Hilarius, D.
Haanen, J. B. A. G.
Blank, C. U.
Aarts, M.
Van den Berkmortel, F.
de Groot, J. W.
Hospers, G. A.
Kapiteijn, E.
Piersma, D.
Van Rijn, R.
Suijkerbuijk, K.
Blokx, W. A. M.
Ten Tije, A.
Van der Veldt, A. A. M.
Vreugdenhil, G.
Boers-Sonderen, M.
van den Eertwegh, A. J. M.
ANNALS OF ONCOLOGY, 2020, 31 : S1431 - S1431
[5] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (vol 124, pg 1222, 2021)
van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
BRITISH JOURNAL OF CANCER, 2021, 124 (10) : 1746 - 1746
[6] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)
van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1362 - 1362
[7] Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
De Meza, Melissa M. M.
Blokx, Willeke A. M.
Bonenkamp, Johannes J. J.
Blank, Christian U. U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
Boers-Sonderen, Marye J. J.
De Groot, Jan Willem B.
Haanen, John B. A. G.
Hospers, Geke A. P.
Kapiteijn, Ellen
Van Not, Olivier J. J.
Piersma, Djura
Van Rijn, Rozemarijn S. S.
Stevense-den Boer, Marion
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
van den Eertwegh, Alfonsus J. M.
Suijkerbuijk, Karijn P. M.
Wouters, Michel W. J. M.
CANCERS, 2023, 15 (02)
[8] Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score-matched recurrence-free, distant metastasis-free, and overall survival analysis
Bloem, Manja
de Meza, Melissa Melanie
Aarts, Maureen J. B.
Van den Berkmortel, Franchette
Blank, Christian U.
Blokx, Willeke
Boers-Sonderen, Marye J.
Bonenkamp, Han J.
de Groot, Jan Willem
Haanen, John
Hospers, Geke
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Rozemarijn
Stevense-den Boer, Marion
Van der Veldt, Astrid Aplonia Maria
Vreugdenhil, Gerard
van den Eertwegh, Alfonsus Johannes Maria
Suijkerbuijk, Karijn
Wouters, Michel W. J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab
Moser, Justin C.
Chen, Danli
Hu-Lieskovan, Siwen
Grossmann, Kenneth F.
Patel, Shiven
Colonna, Sarah, V
Ying, Jian
Hyngstrom, John R.
CANCER MEDICINE, 2019, 8 (18): : 7637 - 7643
[10] Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAFV600-mutant advanced melanoma: a multicenter cohort study
Wu, Junwan
Ding, Qiuyue
Zhang, Qiong
Chen, Qianqi
Wen, Xizhi
Ding, Ya
Li, Jingjing
Chen, Ziluan
Zhang, Tao
Wang, Jiuhong
Huang, Fuxue
Jiang, Hang
Chen, Linbin
Zhou, Qiming
Li, Ke
Zhang, Xiaoshi
Li, Dandan
MEDCOMM, 2025, 6 (03):

← 1 2 3 4 5 →